Pfizer Inc. (NYSE: PFE) announced that its Phase 2 study of tilrekimig met its primary endpoint in adults with moderate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE